Scandinavian Biopharma reports successful results of the ETEC vaccine candidate ETVAX® in a placebo-controlled phase I/II study in infants and children in Bangladesh
Scandinavian Biopharma reports successful results of the oral, inactivated ETEC vaccine candidate ETVAX® against enterotoxigenic E. coli diarrhoea in a placebo-controlled phase I/II study in infants and children from 6 months to 5 years of age in Bangladesh.